Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

Christopher Em Griffiths; KA Papp; Michael Song; B. Randazzo; S Li; Y-K Shen; Chenglong Han; Andrew Blauvelt

doi:10.25251/skin.2.supp.91

Back

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

Article 2018 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2018

Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment

PCM van de Kerkhof, Kristian Reich, C Leonardi, Andrew Blauvelt, Nehal Nailesh Mehta, TF Tsai, R. You, Phil Papanastasiou, M. Milutinovic, Christopher Em Griffiths

Article2019

Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

Christopher Em Griffiths, Kim Papp, Mengsa Song, Megan Miller, Yin You, Y-K Shen, Chenglong Han, Andrew Blauvelt

Article2021

AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL

Christopher Em Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Andrew Blauvelt

Article2019

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Kristian Reich, Christopher Em Griffiths, Kenneth B. Gordon, Kim Papp, Michael Song, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Chenglong Han, Alexa B. Kimball, April W. Armstrong, Peter Foley, Andrew Blauvelt

Article2018

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Michael Song, Shu Li, Yaung‐Kaung Shen, Andrew Blauvelt

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

Abstract

Discussion(0)

Related publications

Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment

Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.